Saturday, Sep 26, 2020 | Last Update : 06:41 PM IST

186th Day Of Lockdown

Maharashtra130045899280634761 Andhra Pradesh6614585881695606 Tamil Nadu5693705138369148 Karnataka5572124503028417 Uttar Pradesh3785333136865450 Delhi2644502284365147 West Bengal2410592110204665 Odisha201059165432820 Telangana1816271501601080 Bihar175898161510881 Assam167374136712625 Kerala160935111327636 Gujarat1303911105923394 Rajasthan1247301042881412 Haryana1205781012731273 Madhya Pradesh117588932382152 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880

DCGI

DCGI issues notice to Serum Institute over AstraZeneca's trial suspension

DGCI sought an immediate reply, saying else "it shall be construed that you have no explanation to offer and action will be taken"

10 Sep 2020 10:29 AM

Serum-Oxford COVID-19 vaccine gets DCGI grant for human trials in India

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India

03 Aug 2020 9:09 AM

Hetero launches COVID-19 drug Favivir at Rs 59 per tablet

The product is available from July 29 at all retail medical outlets across the country and will be sold only on prescription, it said

29 Jul 2020 2:04 PM

FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI

Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients

21 Jul 2020 3:38 PM

Biophore gets DCGI nod to manufacture, export Favipiravir

CEO of Biophore said all starting materials for making favipiravir are either sourced locally or have been developed in-house for use

15 Jul 2020 6:59 AM

ADVERTISEMENT

Hetero gets DCGI nod to launch Remdesivir for COVID-19 treatment

The drug will be available in 100 mg vial which will be administered intravenously in a hospital under healthcare practitioner supervision

21 Jun 2020 2:45 PM

8 Chinese companies get notices for poor quality of APIs

According to a pharma industry body, Indian pharma companies secure 70-75 per cent of APIs from China.

08 Jan 2018 2:06 AM

ADVERTISEMENT
ADVERTISEMENT